- Investing Ideas
- Swiss Pharmaceuticals & Biotech Mid-Large Cap Stocks
Swiss Pharmaceuticals & Biotech Mid-Large Cap Stocks
Results
15
Mid-Large Cap Stocks
15 companies
Novartis
Market Cap: CHF 243.9b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 128.34
7D
2.2%
1Y
26.7%
Roche Holding
Market Cap: CHF 298.4b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 373.80
7D
3.6%
1Y
44.2%
Tecan Group
Market Cap: CHF 2.4b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 193.30
7D
2.2%
1Y
12.4%
Cosmo
Market Cap: CHF 993.6m
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
CMHC
CHF 57.80
7D
1.6%
1Y
-0.9%
SKAN Group
Market Cap: CHF 1.5b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 65.70
7D
11.4%
1Y
0.6%
Sandoz Group
Market Cap: CHF 31.8b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 73.54
7D
0.2%
1Y
47.3%
Galderma Group
Market Cap: CHF 40.0b
Operates as a dermatology company worldwide.
GALD
CHF 171.60
7D
1.2%
1Y
25.2%
Bachem Holding
Market Cap: CHF 5.8b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 77.15
7D
3.1%
1Y
18.9%
Kuros Biosciences
Market Cap: CHF 849.8m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 21.42
7D
-1.6%
1Y
-16.0%
Lonza Group
Market Cap: CHF 41.5b
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 593.80
7D
4.9%
1Y
2.7%
Basilea Pharmaceutica
Market Cap: CHF 809.9m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 65.30
7D
9.6%
1Y
40.3%
Dottikon ES Holding
Market Cap: CHF 3.8b
Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries.
DESN
CHF 276.00
7D
-0.2%
1Y
-5.6%
Siegfried Holding
Market Cap: CHF 3.3b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 74.45
7D
-3.2%
1Y
-13.5%
Idorsia
Market Cap: CHF 1.5b
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.
IDIA
CHF 5.57
7D
-1.1%
1Y
109.8%
PolyPeptide Group
Market Cap: CHF 1.5b
Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.
PPGN
CHF 43.95
7D
-0.1%
1Y
58.4%